Australia-based medical cannabis company Zelira Therapeutics Ltd. said Tuesday that clinical trials showed the company's medical marijuana drug candidate successfully treated chronic insomnia.
According to Zelira Therapeutics, the world-first clinical validation demonstrated that its ZTL-101 medical cannabis treatment is safe and effective for chronic insomnia. The results of the trial open prospects to launch and distribute this product in global markets including the U.S. in the second half of 2020, the company noted.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com